Investment Bank Initiates Coverage of Caliper with Outperform Rating | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Investment bank Wedbush Securities has initiated coverage of Caliper Life Sciences with an 'Outperform' rating and a 12-month price target of $9.

Wedbush analyst Zarak Kurshid cited Caliper's products for the sequencing and diagnostic markets as key drivers for the firm. He also said that recent divestitures provide a "cleaner story" as the firm moves toward sustainable profitability.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: SNP reference panel from the Haplotype Reference Consortium, and more.

Halloran Consulting's Laurie Halloran lists at Stat News the mistakes she sees startup companies make when pursuing a clinical trial.

MIT researchers are using bees to collect and visualize urban microbiome samples, Wired reports.

Reliance on Excel leads to errors in gene name lists, a new Genome Biology paper reports.